REFERENCES
  1. Woś I,  J. Effect of interleukin-6, -17, -21, -22, and -23 and STAT3 on signal transduction pathways and their inhibition in autoimmune arthritis. Immunol Res.  2021;69(1): 26-42.
  2. Bauer S, Groh V, Wu J, Steinle A, Phillips J H, Lanier, L L, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285, 727-9.
  3. Vandenhaute J, Avau A, Filtjens J, Malengier-Devlies B, Imbrechts M, Van den Berghe N, et al. Regulatory Role for NK Cells in a Mouse Model of Systemic Juvenile Idiopathic Arthritis. J Immunol. 2019;203(12):3339-48.
  4. Yang D, Tian Z, Zhang M, Yang W, Tang J, Wu Y, et al. NKG2D+CD4+ T Cells Kill Regulatory T Cells in a NKG2D-NKG2D Ligand-Dependent Manner in Systemic Lupus Erythematosus. Sci Rep. 2017;7(1):1288.
  5. Legroux L, Moratalla A C, Laurent C, Deblois G, Verstraeten S L, Arbour N. NKG2D and its Ligand MULT1 Contribute to Disease Progression in a Mouse Model of Multiple Sclerosis. Front Immunol. 2019;10:154.
  6. Phoksawat W, Jumnainsong A, Leelayuwat N, Leelayuwat C. Aberrant NKG2D expression with IL-17 production of CD4+ T subsets in patients with type 2 diabetes. Immunobiology. 2017;222(10):944-51.
  7. Pariente B, Mocan I, Camus M, Dutertre C-A, Ettersperger J, Cattan P, et al. Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn’s disease. Gastroenterology. 2011;141(1):217-26.
  8. Andersson A K, Sumariwalla P F, McCann F E, Amjadi P, Chang C, McNamee K, et al. Blockade of NKG2D ameliorates disease in mice with collagen-induced arthritis: a potential pathogenic role in chronic inflammatory arthritis. Arthritis Rheum. 2011;63(9):2617-29.
  9. Dai Z, Turtle C J, Booth G C, Riddell S R, Gooley T A, Stevens A M, et al. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med. 2009;206(4):793-805.
  10. Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K. NKG2D Natural Killer Cell Receptor-A Short Description and Potential Clinical Applications. Cells. 2021;10(6):1420.
  11. Petty R E, Southwood T R, Manners P, Baum J, Glass D N, Goldenberg J, et al., International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001, J Rheumatol, 2004, 31: 390-2.
  12. Zafar S, Sorsa S, Siurala M, Hemminki O, Havunen R, Cervera-Carrascon V, et al. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncoimmunology. 2018;7(10):e1490856.
  13. Jinushi M, Takehara T, Kanto T, Tatsumi T, Groh V, Spies T, et al. Critical role of MHC class I-related chain A and B expression on IFN-stimulated dendritic cells in NK cell activation: impairment in chronic hepatitis C infection. J Immunol. 2003,170:1249.
  14. Tong J, Buch S, Yao H, Wu C, T H-I, Wang Y, et al. Monocytes-derived macrophages mediated stable expression of human brain-derivedneurotrophic factor, a novel therapeutic strategy for neuroAIDS. PLoS One. 2014 ;9(2):e82030.
  15. Nasri M, Karimi A, Allahbakhshian Farsani M. Production, purification and titration of a lentivirus-based vector for gene delivery purposes. Cytotechnology. 2014;66(6):1031-8.
  16. Marina B, Chiara R. The Role of Natural Killer Group 2, Member D in Chronic Inflammation and Autoimmunity. Front Immunol. 2018;9:1219. doi: 10.3389/fimmu.2018.01219. eCollection 2018.
  17. Wielińska J, Tarassi K, Iwaszko M, Kościńska K, Wysoczańska B, Mole E, et al. Shared epitope and polymorphism of MICA and NKG2D encoding genes in Greek and Polish patients with rheumatoid arthritis. Eur J Immunol. 2021;46(1):92-8.
  18. Mariaselvam C M, Tamouza R, Krishnamoorthy R, Charron D, Misra D P, Jain V K, et al. Association of NKG2D gene variants with susceptibility and severity of rheumatoid arthritis. Clin Exp Immunol. 2017;187(3):369-75.
  19. Fechtenbaum M, Desoutter J, Delvallez G, Brochot E. MICA and NKG2D variants as risk factors in spondyloarthritis: a case control study. Genes Immun. 2019;20(7):599-605.
  20. Iwaszko M, Świerkot J, Kolossa K, Jeka S, Wiland P, Bogunia-Kubik K. Influence of NKG2D Genetic Variants on Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis. Genes (Basel). 2018;9(2):64.
  21. Mariaselvam C M, Boukouaci W, Charron D, Krishnamoorthy R, Tamouza R, Misra D P et al. Association of MICA-129 polymorphism and circulating soluble MICA level with rheumatoid arthritis in a south Indian Tamil population. Int J Rheum Dis. 2018;21(3):656-63.
  22. Iwaszko M, Świerkot J, Dratwa M, Wysoczańska B, Korman L, Bugaj B, et al. Association of MICA-129Met/Val polymorphism with clinical outcome of anti-TNF therapy and MICA serum levels in patients with rheumatoid Arthritis. Pharmacogenomics J. 2020;20(6):760-769.
  23. Song G G, Kim J-H, Lee Y H. Associations between the major histocompatibility complex class I chain-related gene A trans membrane (MICA-TM) polymorphism and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. Rheumatol Int. 2014;34:117-23.
  24. Correll C K, Binstadt B A. Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis. Pediatr Res. 2014 ;75(1-2):176-83
  25. Ombrello M J, Arthur V L, Remmers E F, Hinks A, Tachmazidou I, Grom A A, et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis. 2017;76(5):906-13
  26. Lotte N, Janneke G P, Sebastiaan J V , van Loosdregt J. Restoring T Cell Tolerance, Exploring the Potential of Histone Deacetylase Inhibitors for the Treatment of Juvenile Idiopathic Arthritis. Front Immunol. 2019;10:151
  27. Mellins E D, Macaubas C, Grom A A. Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions. Nat Rev Rheumatol. 2011;7:416-26.
  28. Mariotte A, Bernardi L, Macquin C, DeCauwer A, Kotova I, Blűml S, et al. NKG2D ligands in inflammatory joint diseases: analysis in human samples and mouse models. Clin Exp Rheumatol. 2021;39(5):982-7.
  29. Babic M, Dimitropoulos C, Hammer Q, Stehle C, Heinrich F, Sarsenbayeva A, et al. NK cell receptor NKG2D enforces proinflammatory features and pathogenicity of Th1 and Th17 cells. J Exp Med. 2020;217(8):e20190133.
  30. Saraiva M, Vieira P, O’Garra A. Biology and therapeutic potential of interleukin-10. J Exp Med. 2020; 217(1): e20190418.
  31. Basu A, Ramamoorthi G, Albert G, Gallen C, Beyer A, Snyder C, et al. Differentiation and Regulation of TH Cells: A Balancing Act for Cancer Immunotherapy. Front Immunol. 2021; 12: 669474.